Richard Aplenc MD
Professor of Pediatrics, Perelman School of Medicine
Join to View Full Profile
3401 Civic Center BlvdChildren's Hospital Of Philadelphia - Hem/OncPhiladelphia, PA 19104
Phone+1 215-590-3535
Fax+1 215-590-3992
Dr. Aplenc is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 1997 - 2000
University of California (San Diego) Medical CenterResidency, Pediatrics, 1994 - 1997
University of Virginia School of MedicineClass of 1994
Certifications & Licensure
PA State Medical License 1997 - 2026
CA State Medical License 1996 - 2000
American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes Start of enrollment: 2002 Jul 01
- Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate Start of enrollment: 2006 Mar 01
- Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2006 Aug 01
Publications & Presentations
PubMed
- 1 citationsDiagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel.C Michel Zwaan, Sarah K Tasian, Richard Aplenc, Lisa E Brodersen, Barbara Buldini
Blood. 2026-04-02 - Feasibility of Automated Laboratory Data Ascertainment and Transfer From Hospitals Into Medidata Rave Across Pediatric National Cancer Institute-Supported Cooperative ...Tamara P Miller, Richard Aplenc, Charles Minard, Shelly Lensing, Yu Wang
JCO Clinical Cancer Informatics. 2026-04-01 - Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort.Daniel J Zheng, Gary Hettinger, Catherine Aftandilian, Kira Bona, Emi H Caywood
Journal of the National Cancer Institute. 2026-04-01
Abstracts/Posters
- Disparities in Barriers and Facilitators of Acute Leukemia Diagnosis in Young PatientsRichard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report ...Richard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Response to Sorafenib in FLT3/ITD AML Is Depedent on Co-Occurring Mutational ProfileRichard Aplenc, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Effect of intensification of induction II chemotherapy and liberalization of stem cell donor source on outcome for children with high risk acute myeloid leukemia: A re...2019 ASCO Annual Meeting - 6/1/2019
- Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Pediatric Patient-Reported Symptom Tracking in Oncology (Pedi-PReSTO): A Feasibility Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- Emily Whitehead, First Pediatric Patient to Receive CAR T-cell Therapy, Celebrates Cure 10 Years LaterMay 11th, 2022
- Remembering Alvin Zipursky, Paul Frenette, and MoreSeptember 1st, 2021
- Children's Hospital of Philadelphia Names Chief of Hematologic MalignanciesJuly 13th, 2021
Grant Support
- Cancer Clinical Epidemiology Training GrantUNIVERSITY OF PENNSYLVANIA1992–2028
- Database Harmonization for Creation and Validation of Outcome Assessments and Prediction Tools for Metachromatic Leukodystrophy (MLD)CHILDREN'S HOSP OF PHILADELPHIA2025–2027
- Predicting and Monitoring for Cardiac Toxicity in Pediatric AMLCHILDREN'S HOSP OF PHILADELPHIA2023–2027
- Genetic Predictors Of AML Treatment ResponseNational Cancer Institute2010–2012
- Genetic Predictors Of Leukemia Therapy ResponseNational Cancer Institute2005–2009
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
